Structural Bioinformatics of Viral Envelope Proteins and Entry Mechanisms

1. Introduction

Viral envelope proteins mediate the first critical steps of infection: attachment to host cell receptors and fusion of the viral membrane with a cellular membrane. These processes define host range, tissue tropism, and zoonotic potential. In veterinary virology, envelope proteins of pathogens such as avian influenza virus, infectious bronchitis virus (IBV), equine infectious anemia virus (EIAV), henipaviruses, and porcine reproductive and respiratory syndrome virus are prime targets for vaccine design and therapeutic intervention [1, 2, 3]. Understanding the structural rearrangements that govern membrane fusion requires integrating experimental techniques (cryo-electron microscopy, X-ray crystallography) with computational methods collectively termed structural bioinformatics. This review covers the classification of viral fusion proteins, the biophysical principles of entry, and the computational tools used to model and visualize these processes, with exclusive reference to veterinary and comparative virology literature.

2. Classification of Viral Fusion Proteins

Viral envelope glycoproteins are broadly divided into three structural classes based on their fusion mechanism and tertiary fold. Class I proteins include the hemagglutinin (HA) of orthomyxoviruses, the fusion (F) protein of paramyxoviruses, the spike (S) protein of coronaviruses, the Env glycoprotein of retroviruses, and the glycoprotein (GP) of filoviruses [4]. Class II proteins are found in flaviviruses (envelope E protein) and alphaviruses (E1/E2). Class III proteins are represented by rhabdovirus G and herpesvirus gB. Each class undergoes profound conformational changes from a metastable prefusion state to a stable postfusion state, driving membrane merger [4]. The ability to predict these states computationally has been advanced by deep learning methods such as AlphaFold2 [4].

3. Class I Fusion Proteins: Architecture and Rearrangement

Class I fusion proteins are trimeric and characterized by an extended central coiled-coil core. In the prefusion conformation, the fusion peptide is buried within the protein. Upon triggering by receptor binding or low pH, the fusion peptide is extruded and inserts into the target membrane. The protein then refolds into a six-helix bundle (6HB) that brings the viral and cellular membranes into close apposition [4]. The transition is irreversible and renders the postfusion state highly stable.

For influenza A virus HA, the fusion loop region drives membrane insertion. Stabilization of the prefusion conformation is a key strategy for vaccine antigen design, as demonstrated for H5 clade 2.3.4.4b and other subtypes [5, 6]. Algorithm-optimized mRNA vaccines encoding stabilized HA elicit broader immune responses in animal models [6]. Similarly, the class I F protein of henipaviruses is targeted by cross-species neutralizing antibodies that block conformational rearrangements [7].

Coronavirus S proteins are also class I. The S1 subunit mediates receptor binding, while S2 contains the fusion machinery. The prefusion S trimer must be stabilized for immunogenicity. Computational design of mRNA vaccines against betacoronaviruses, including bat-origin alphacoronaviruses that use CEACAM6 as an entry receptor [8], has relied on structural bioinformatics to select stabilizing mutations [9, 10].

4. Class II Fusion Proteins

Class II fusion proteins lack extended coiled-coil regions and instead use a three-domain architecture with a fusion loop at the tip. The dengue virus envelope protein is the archetype; its prefusion form arranges as a head-to-tail dimer on the virion surface. Acidic pH triggers a dramatic reorganization to a trimeric postfusion form [11]. Computational screening for inhibitors targeting the prefusion state of the dengue envelope protein has been performed using physics- and AI-based multi-tier screening [11]. In alphaviruses, the E1 glycoprotein acts as the fusion effector, while E2 regulates receptor binding.

5. Class III Fusion Proteins

Class III proteins combine features of both class I and II. The vesicular stomatitis virus G protein transitions from a trimeric prefusion form to a postfusion trimer with a central coiled-coil, but also contains a fusion loop rather than a peptide. Herpesvirus gB is similarly complex. Veterinary herpesviruses such as bovine herpesvirus type 1 and felid herpesvirus 1 use gB for entry, but structural studies remain limited compared to human herpesviruses. Computational modeling using homology and AlphaFold2 can predict these conformations, though validation requires experimental structures.

6. Receptor Binding and Fusion Triggers

Envelope proteins first engage specific host receptors. For influenza A virus HA, the receptor is sialic acid, and the binding specificity (alpha2-3 vs alpha2-6) determines host tropism. For coronavirus S, receptors include ACE2 (sarbecoviruses), DPP4 (MERS-like), and CEACAM6 (some alphacoronaviruses) [8]. Fusion is triggered by low pH in endosomes (e.g., influenza, flaviviruses) or by receptor binding at neutral pH (e.g., HIV, paramyxoviruses). The trigger induces conformational changes that release the fusion peptide. These events have been extensively modeled with molecular dynamics simulations and experimental biophysics [4, 11].

7. Computational Methods for Structural Bioinformatics

7.1. Homology Modeling and Fold Recognition

When experimental structures are unavailable, homology modeling using templates from related viruses generates useful models. For veterinary coronaviruses such as IBV, the S protein structure can be predicted based on known S structures. The genotype diversity of IBV in different regions, including GI-1, GI-13, and GI-23, impacts the accuracy of such models [2].

7.2. Deep Learning: AlphaFold2 and Beyond

AlphaFold2 has revolutionized protein structure prediction. A dedicated study demonstrated that AlphaFold2 can reliably predict both prefusion and postfusion conformations of class I viral fusion proteins when the models are guided by experimental constraints or multiple sequence alignments [4]. This capability is critical for viruses where only one conformational state has been crystallized, such as for many paramyxovirus and coronavirus spike ectodomains. The predicted models can be superimposed in a 3D viewer to visualize the large-scale domain movements underlying fusion.

7.3. Molecular Dynamics and Docking

Molecular dynamics simulations explore the energetic landscape of envelope proteins, capturing transient states relevant to fusion intermediate trapping. Docking studies with host receptors or small-molecule inhibitors inform drug and vaccine design. QSAR-guided fragment-based drug design has been applied to Ebola virus glycoprotein to identify monoterpenoid inhibitors [12]. Similarly, immunoinformatics-based epitope prediction combined with docking of natural compounds has been reported for MERS-CoV [13].

7.4. Immunoinformatics and Epitope Mapping

Linear and conformational epitope prediction helps design multi-epitope vaccines. For EIAV, an immunoinformatic approach identified high-coverage epitopes in the Env polyprotein [1]. For henipaviruses, neutralizing antibodies targeting both fusion and receptor-binding proteins have been characterized structurally [7]. Glycan shielding analysis reveals how mutations alter epitope accessibility, as shown for SARS-CoV-2 Omicron variants and for influenza HA imprinting [14, 15, 16]. Multi-view transformer models can map mutation hotspots and drift risk for influenza HA and NA [17].

7.5. mRNA Vaccine Design Platforms

Structural bioinformatics underpins the rational design of mRNA vaccines. Platforms such as VaxLab enable rapid multistrategy design by combining antigen structure optimization (e.g., prefusion stabilization) with codon optimization and innate immune evasion [18]. The design of H5 influenza mRNA vaccines using algorithm-optimized sequences exemplifies this workflow [6]. For veterinary betacoronaviruses, multi-epitope mRNA vaccines have been designed in silico using immunoinformatics [9].

8. Visualizing Prefusion and Postfusion States

Side-by-side visualization of prefusion and postfusion states is essential for understanding the fusion mechanism. Using coordinate files from the Protein Data Bank (e.g., prefusion PDB ID 5JTB for coronavirus S, postfusion 6B3A) or from predicted models [4], one can superimpose the structures using alignment of conserved domains (e.g., the central helix in class I proteins). The fusion peptide moves from a buried pocket to the membrane interface, while the helical bundle collapses. In a 3D viewer, these changes are evident as a dramatic extension of the coiled-coil and a reorientation of the fusion loop. The same approach helps identify neutralizing antibody epitopes that are only present in the prefusion state, guiding immunization strategies.

graph TD
    A[Viral genome sequencing], > B{Envelope protein gene identification}
    B, > C[Multiple sequence alignment]
    C, > D[Phylogenetic analysis and genotype assignment]
    D, > E[Structural template selection]
    E, > F[AlphaFold2/ homology modeling]
    F, > G{Prefusion vs postfusion}
    G, > H[Generate prefusion state model]
    G, > I[Generate postfusion state model]
    H, > J[Coordinate superposition in 3D viewer]
    I, > J
    J, > K[Movement analysis: fusion loop, helix extension]
    K, > L[Epitope mapping and stabilization design]
    L, > M[Candidate vaccine antigen]

9. Applications in Veterinary Virology

9.1. Avian Influenza Virus

The H5N1 and H7N9 subtypes cause devastating outbreaks in poultry. Hemagglutinin stabilization in the prefusion state improves vaccine-elicited neutralizing antibody responses [5]. Cross-reactive antibodies from seasonal influenza vaccination may offer partial protection against emerging bovine H5N1 clade 2.3.4.4b [3]. Genomic surveillance using structural bioinformatics enables fitness tracking and drift risk scoring [17, 19].

9.2. Infectious Bronchitis Virus

IBV S protein genotypes GI-1, GI-13, and GI-23 circulate in poultry flocks, with implications for cross-protection [2]. Structural modeling of S glycoprotein helps predict serotype-specific epitopes.

9.3. Henipaviruses

Hendra and Nipah viruses use a class I F protein and a G attachment protein. Cross-species neutralizing antibodies that block F or G binding are being developed [7]. Structural bioinformatics supports epitope identification and antibody optimization.

9.4. Equine Infectious Anemia Virus

EIAV Env is subject to high genetic variability. An immunoinformatics-based vaccine design covering multiple epitopes has been proposed [1].

10. Antibody Responses and Immune Evasion

Envelope proteins are under continuous selective pressure. Glycan shielding masks conserved epitopes on influenza HA [14, 15] and HIV Env [20]. B cell imprinting in children impairs stalk-directed antibody responses [16]. In veterinary hosts, similar imprinting may shape vaccine efficacy. Computational tools can predict escape mutations and guide vaccine updates [21, 22]. Broadly neutralizing antibodies against the HIV-1 V3 glycan site have been identified [20], and class 1/4 neutralizing antibodies against sarbecoviruses are effective in animal models [23]. The structural landscape profiling of antibody functionality using AI provides a method for mining potent neutralizing antibodies [24].

11. Limitations and Future Directions

Despite advances, predicting prefusion versus postfusion states de novo remains challenging without experimental constraints. The energy landscape of fusion is steep, and intermediate states are transient. Cryo-electron microscopy continues to provide high-resolution structures that serve as templates [25]. Nanodisc platforms allow presentation of native glycoproteins for vaccine analytics [25]. Integration of multi-omics data with structural models will improve predictions of host range and zoonotic risk.

12. Conclusion

Structural bioinformatics provides a powerful framework for dissecting viral entry mechanisms. By combining sequence analysis, structure prediction, and biophysical simulation, researchers can map conformational rearrangements, design stabilized vaccine antigens, and identify vulnerable epitopes. These approaches are directly applicable to veterinary pathogens, enabling better control of emerging and endemic viral diseases in animal populations.

References

[1] Garay E, Garay AS, Veaute C et al. A High-Coverage Epitope-Based Vaccine Design for EIAV Envelope Polyprotein Using an Immunoinformatic Approach. Vet Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41893696/

[2] Ardicli O, Kanar TS, Ucar KB et al. First Molecular Characterization and Comprehensive Bioinformatic Analysis of Avian Infectious Bronchitis Virus from Uzbekistan Reveals GI-1, GI-13, and GI-23 Genotypes in Broilers. Viruses. 2026. https://pubmed.ncbi.nlm.nih.gov/41902240/

[3] Li Y, Zhang X, Zhou X et al. Cross-Reactive Antibody Responses to Emerging Bovine H5N1 Clade 2.3.4.4b Following Seasonal Influenza Vaccination: Implications for Pandemic Preparedness. Viral Immunol. 2026. https://pubmed.ncbi.nlm.nih.gov/41697105/

[4] Gülesen S, Most V, Schoeder CT et al. Prediction of pre- and postfusion conformations of class I fusion proteins with AlphaFold2. PLoS One. 2026. https://pubmed.ncbi.nlm.nih.gov/42302011/

[5] Dosey A, Dadonaite B, Gillespie RA et al. Stabilization of the H5 clade 2.3.4.4b hemagglutinin improves vaccine-elicited neutralizing antibody responses in mice. Sci Transl Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41779867/

[6] Wang L, Peng Z, He C et al. Algorithm-Optimized H5 Influenza mRNA Vaccine Induces Broad Immune Responses. Int J Mol Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42196525/

[7] Guzmán-Solís AA, Ouizougun-Oubari M, Escaffre O et al. A cocktail of human mAbs targeting the henipavirus fusion and receptor binding proteins provides cross-species neutralization. Sci Transl Med. 2026. https://pubmed.ncbi.nlm.nih.gov/42268934/

[8] Gallo G, Di Nardo A, Lugano D et al. Heart-nosed bat alphacoronaviruses use human CEACAM6 to enter cells. Nature. 2026. https://pubmed.ncbi.nlm.nih.gov/42020746/

[9] Zheng N, Xu Y. In silico design of a novel multi-epitope mRNA vaccine candidate for BtHKU5-CoV-2 using immunoinformatics. PLoS Negl Trop Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/41931545/

[10] Rahimnahal S, Yousefizadeh S, Mohammadi Y. Designing a novel vaccine against COVID-19 based on spike SARS-Cov-2 notable mutations using immunoinformatics approaches. PLoS One. 2026. https://pubmed.ncbi.nlm.nih.gov/41746934/

[11] Pravin MA, Khan MA, Singh SK. Identification of potent inhibitors targeting the pre-fusion DENV envelope protein: A consensus physics-and AI-based in silico multi-tier screening approach. Biochem Biophys Res Commun. 2026. https://pubmed.ncbi.nlm.nih.gov/42008872/

[12] Ait Lahcen N, Liman W, Zekri S et al. QSAR-Guided and Fragment-Based Drug Design of Monoterpenoid Inhibitors Targeting Ebola Virus Glycoprotein. Int J Mol Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41977174/

[13] Sugumar M, Pragalath S, Kugarajah V. Immunoinformatics-based epitope prediction in MERS-CoV and docking analysis of Catharanthus roseus compounds for drug discovery. Comput Biol Chem. 2026. https://pubmed.ncbi.nlm.nih.gov/42218862/

[14] Kumar A, Yadav AJ, Tripathi T et al. Glycan shielding and epitope reorganization drive sotrovimab resistance in SARS-CoV-2 Omicron variants. Arch Biochem Biophys. 2026. https://pubmed.ncbi.nlm.nih.gov/42128042/

[15] Li SH, Wang B, Jo G et al. Childhood immunological imprinting of cross-subtype antibodies targeting the hemagglutinin head domain of influenza viruses. Cell Host Microbe. 2026. https://pubmed.ncbi.nlm.nih.gov/42049037/

[16] Sun J, Jo G, Troxell CA et al. B cell imprinting in children impairs antibodies to the haemagglutinin stalk. Nature. 2026. https://pubmed.ncbi.nlm.nih.gov/41813896/

[17] Agarwal P, Yogarayan S, Sayeed MS et al. Multi-View Transformers for Structure-Aware HA-NA Drift Risk Scoring and Mutation Hotspot Mapping. Viruses. 2026. https://pubmed.ncbi.nlm.nih.gov/42043210/

[18] Kim J, Han Y, Kwon CY et al. VaxLab: integrated platform for rapid multistrategy mRNA vaccine design. Exp Mol Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41951904/

[19] Lei ZY, Jin QT, Zhang XM et al. Genomic-epidemiological analysis of 15 million SARS-CoV-2 genomes reveals accelerated fitness gain of JN.1 lineage. Virol Sin. 2026. https://pubmed.ncbi.nlm.nih.gov/41962740/

[20] Gieselmann L, DeLaitsch AT, Rohde M et al. Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332(gp120) glycan-independent epitope. Nat Immunol. 2026. https://pubmed.ncbi.nlm.nih.gov/41634487/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[21] Lamb KD, Hughes J, Lytras S et al. From single-sequences to evolutionary trajectories: protein language models capture the evolutionary potential of SARS-CoV-2. Nat Commun. 2026. https://pubmed.ncbi.nlm.nih.gov/41714330/

[22] Lin YW, Guo LZ, Tsai YT et al. Evolutionary patterns of pH1N1 and H3N2 in relation to vaccine use. BMC Genomics. 2026. https://pubmed.ncbi.nlm.nih.gov/41652567/

[23] Skelly AN, Fan C, Keeffe JR et al. mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model. Proc Natl Acad Sci U S A. 2026. https://pubmed.ncbi.nlm.nih.gov/42258728/

[24] Terekhov SS, Ivanisenko NV, Zhang N et al. Mining antibody functionality via AI-guided structural landscape profiling. Nat Commun. 2026. https://pubmed.ncbi.nlm.nih.gov/41833937/

[25] Rantalainen K, Liguori A, Ozorowski G et al. Virus glycoprotein nanodisc platform for vaccine analytics. Nat Commun. 2026. https://pubmed.ncbi.nlm.nih.gov/41667448/

[26] Ramadan MA, ElGohary HM, Faraag AH et al. A protocol for computational design of mRNA vaccines with high functionality and specificity. Biol Direct. 2026. https://pubmed.ncbi.nlm.nih.gov/42288920/

[27] Xi K, Zhang X, Li J et al. Dual role of Japanese encephalitis virus fusion loop peptide antibodies in Zika virus infection. PLoS Negl Trop Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42081585/

[28] Amjad MN, Wang J, Shen B et al. Phylodynamics and molecular epidemiology of the respiratory syncytial virus fusion protein in China. Microbiol Spectr. 2026. https://pubmed.ncbi.nlm.nih.gov/42065599/

[29] Guenaga J, Ádori M, Bale S et al. Vaccination generates broadly cross-neutralizing antibodies to the HIV Env apex. Nature. 2026. https://pubmed.ncbi.nlm.nih.gov/42056526/

[30] Fischer AA, Corcoran M, Brouwer PJM et al. Genetically diverse influenza antibodies highlight the role of IG germline gene variation and inform population-comprehensive vaccine strategies. Immunity. 2026. https://pubmed.ncbi.nlm.nih.gov/41895293/

[31] Kadam RU, Juraszek J, Brandenburg B et al. Small molecule-constrained paratope mimetic bicyclic peptides as potent inhibitors of group 1 and 2 influenza A virus hemagglutinins. Proc Natl Acad Sci U S A. 2026. https://pubmed.ncbi.nlm.nih.gov/41875158/

[32] De Rosa SC, Gravett RM, Hahn WO et al. DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant protein. Vaccine. 2026. https://pubmed.ncbi.nlm.nih.gov/41865485/

[33] Dubey A, Kumar M, Tufail A et al. Allophycocyanin inhibits HIV-1 gp120 and reverse transcriptase through enthalpy-driven binding and antioxidative protection: integrative computational and experimental insights. Sci Rep. 2026. https://pubmed.ncbi.nlm.nih.gov/41851190/

[34] Asghari M, Golalipour M, Memarian A et al. Presentation of multiple copies of a non-dominant surface epitope by circular RNA effectively induce an immune response against SARS-CoV-2. J Virol Methods. 2026. https://pubmed.ncbi.nlm.nih.gov/41724332/

[35] He L, Lee YZ, Zhang YN et al. Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design. Nat Commun. 2026. https://pubmed.ncbi.nlm.nih.gov/41673395/